Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.
|Videos|November 3, 2020
HIFU for prostate cancer: How it works, criteria for treatment, and contraindications
Author(s)Urology Times staff
Samuel J. Peretsman, MD, explains how he incorporated HIFU into his practice.
Advertisement
In part 1 of this 3-part interview, Samuel J. Peretsman, MD, discusses high-intensity focused ultrasound with J. Brantley Thrasher, MD.
Advertisement
Related to this article
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
4
Q&A: Where ProACT fits in the male stress urinary incontinence algorithm
5